Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.50 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.50 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11597123 | 1.00 | CYP1A2 (0.60) | CYP1A2TDP1ALDH1A1HIF1AMAPK1 | |
| SCHEMBL27961047 | 0.88 | CYP1A2 (0.68) | CYP1A2TDP1ALDH1A1HIF1AMAPK1 | |
| SCHEMBL1296998 | 0.87 | CYP1A2 (0.62) | CYP1A2TDP1ALDH1A1HIF1AMAPK1 | |
| SCHEMBL10890268 | 0.85 | CYP1A2 (0.64) | CYP1A2TDP1ALDH1A1HIF1AMAPK1 | |
| SCHEMBL10891708 | 0.85 | CYP1A2 (0.64) | CYP1A2TDP1ALDH1A1HIF1AMAPK1 | |
| SCHEMBL20718830 | 0.84 | ALDH1A1 (0.50) | CYP1A2TDP1ALDH1A1HIF1ATSHR | |
| SCHEMBL29780563 | 0.84 | ALDH1A1 (0.50) | CYP1A2TDP1ALDH1A1HIF1ATSHR | |
| SCHEMBL5222516 | 0.84 | CYP3A4 (0.53) | CYP1A2TDP1ALDH1A1TSHRMEN1 | |
| SCHEMBL8593072 | 0.83 | CYP1A2 (0.62) | CYP1A2TDP1ALDH1A1HIF1AMAPK1 | |
| SCHEMBL5333075 | 0.82 | CYP1A2 (0.66) | CYP1A2TDP1ALDH1A1HIF1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006060654-A2 | PESTICIDAL COMPOSITIONS AND METHODS | DIVERGENCE, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20050203067-A1 | Pesticidal compositions and methods | DIVERGENCE, INC. | 2005-09-15 | — | — | US | claimed |
| US-4104462-A | Cardioactive adenosine nitrates | HOFFMANN-LA ROCHE INC. (US) | 1978-08-01 | — | — | US | claimed |
| US-9968683-B2 | Method for conjugating molecules | ORGANOLINX CORP. (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20160206748-A1 | METHOD FOR CONJUGATING MOLECULES | ORGANOLINX CORP. (CA) | 2016-07-21 | — | — | US | disclosed |
| WO-2014015675-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| EP-1477186-B1 | ANTIPRURITICS | SHIONOGI & CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-7420053-B2 | 2-imino-1,3-thiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2008-09-02 | — | — | US | disclosed |
| EP-1375489-B1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-20050203067-A1 | Pesticidal compositions and methods | DIVERGENCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-6916806-B2 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | HANASAKI KOJI (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6818640-B1 | BIND SELECTIVELY TO CANNABINOID 2 RECEPTOR; ANTIINFLAMMATORY AGENTS | SHIONOGI & CO., LTD. (JP) | 2004-11-16 | — | — | US | disclosed |
| US-20040116326-A1 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1375489-A1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1219612-A1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | CYP1A2 2499/4885TDP1 4762/4885ALDH1A1 4118/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CYP1A2 2356/4885TDP1 4657/4885ALDH1A1 3580/4885 |
| US-20050203067-A1 | Pesticidal compositions and methods | ACHE, DDT, PTMS | CYP1A2 603/4885TDP1 2337/4885ALDH1A1 3205/4885 |
| US-20160206748-A1 | METHOD FOR CONJUGATING MOLECULES | AADAC, DDT, ALDH3A1 | CYP1A2 598/4885TDP1 3284/4885ALDH1A1 13/4885 |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | CNR2, CNR1, HTR2C | CYP1A2 817/4885TDP1 3661/4885ALDH1A1 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.